Melanotan 2 5 mg

Melanotan II 5 mg Dragon Pharma — Overview

Melanotan II 5 mg Dragon Pharma is a synthetic cyclic analogue of alpha-melanocyte stimulating hormone (α-MSH) in a compact 5 mg vial format. It activates melanocortin receptors in the skin and central nervous system, producing two primary effects: accelerated melanogenesis (skin darkening via MC1R) and MC4 receptor-mediated enhancement of libido and sexual function. The 5 mg vial is the same compound as the 10 mg version at half the quantity — it provides 10 doses at the standard 0.5 mg maintenance dose and is suited to users who are already established on a protocol and prefer smaller, more frequent restocking over a larger upfront volume.

This page covers the melanocortin receptor system and how Melanotan II engages it, the compound's documented effects on pigmentation and sexual function, the reconstitution and dosing protocol for the 5 mg vial, and side effect management.

About the Compound: Melanotan II

Alpha-melanocyte stimulating hormone (α-MSH) is an endogenous peptide derived from proopiomelanocortin (POMC) that acts on five melanocortin receptor subtypes (MC1R through MC5R). In the skin, MC1R activation on melanocytes triggers the intracellular signaling cascade that upregulates eumelanin (brown/black pigment) production — the same mechanism that produces tanning after UV exposure, but initiated pharmacologically rather than by UV-induced DNA stress signaling. In the central nervous system, MC4R activation in the hypothalamus and limbic system modulates sexual arousal, libido, and, in men, facilitates penile erection through pro-erectile pathways.

Melanotan II is a cyclic heptapeptide analogue of α-MSH. The ring structure confers resistance to proteolytic degradation, extending the half-life to several hours and producing substantially greater receptor potency than the native linear peptide. This cyclization gives MT-II broad activity across MC1R, MC3R, MC4R, and MC5R simultaneously — the basis of both its tanning and sexual function effects, and its side effect profile.

What Melanotan II Does

Melanotan II produces two mechanistically distinct categories of effects through its melanocortin receptor activity:

• Skin pigmentation (MC1R) — activation of MC1R on melanocytes upregulates tyrosinase enzyme activity and shifts melanin synthesis toward eumelanin (dark brown/black pigment) over phaeomelanin (red/yellow); this produces darkening of the skin that is amplified by any UV exposure, allowing users to achieve a visible tan with significantly shorter sun or tanning bed exposure than would otherwise be required; the pigment change is cumulative and develops progressively over the loading phase
• Libido and sexual function (MC4R) — MC4R activation in the hypothalamus and limbic regions increases sexual arousal and desire in both men and women; in men, MC4R-mediated pathways facilitate spontaneous erections and enhance erectile response to stimulation; the sexual effects occur at lower doses than are typically needed for significant tanning and can appear within hours of the first injection
• Appetite suppression (MC3R/MC4R) — melanocortin receptor activation in the hypothalamus has a secondary appetite-suppressing effect; this is typically mild at tanning doses but may contribute to modest reductions in food intake during the loading phase
• Darkening of existing pigmented lesions — moles, freckles, and other melanocyte-rich lesions respond more strongly to MC1R activation than surrounding skin; pre-existing benign moles typically darken visibly during loading; a baseline skin assessment before starting is worth performing

Who It's For

• Established users restocking on maintenance protocol — once the loading phase is complete and the target pigmentation level is reached, the maintenance dose of 0.5 mg two to three times per week is low enough that the 5 mg vial provides approximately 3–5 weeks of supply; for users who prefer ordering frequently in smaller amounts rather than stockpiling, the 5 mg format is the natural fit
• Users new to Melanotan II starting with a smaller trial quantity — the 5 mg vial allows first-time users to assess individual response to MT-II (sensitivity to nausea, degree of tanning response, sexual effects) before committing to a larger volume; at 0.5 mg/day, the 5 mg vial covers roughly 10 days of loading, which is sufficient to gauge tolerability and early tanning results
• Users targeting libido or sexual function on an as-needed basis — when MT-II is used primarily for the MC4R sexual effects rather than sustained tanning (0.25–0.5 mg pre-activity, on demand), the 5 mg vial provides 10–20 on-demand doses; for this use pattern, the 5 mg format is practical and avoids unnecessary product sitting reconstituted beyond its 30-day window
• Users who should consider alternatives: those planning a full loading phase from scratch will go through the 5 mg vial quickly at 0.5–1 mg/day; the 10 mg vial provides better economy for the loading phase; those who want the sexual effects without any tanning are better served by PT-141

Context & Related Products

The 5 mg vial occupies the same pharmacological space as the 10 mg format. The selection between them is a practical quantity decision rather than a mechanistic one:

Reconstitution supply:

Side Effects & Management

The side effect profile of the 5 mg vial is identical to the 10 mg format — it is the same compound. Effects arise from broad melanocortin receptor activity and are most pronounced during the loading phase. They diminish as the body accommodates to the peptide.

References